Dr Pierre Wallemacq, is Professor at the Université Catholique de Louvain, Medical school in Brussels, Belgium. He teaches clinical chemistry, toxicology and clinical pharmacokinetics, and is the vice president of the Biomedical Sciences School. He is one of the co-founders of the Louvain centre for Toxicology and Applied Pharmacology (LTAP) in the Medical School, and supervises several PhD theses and post-doc fellows. He is also head of Clinical Chemistry Department in the Cliniques universitaires St Luc, Brussels, in charge of the automated CoreLab platform as well as of the analytical biochemistry platform regrouping specific activities such as TDM, clinical toxicology, forensic toxicology, but also special chemistry and endocrinology (GC, HPLC, UPLC, LC-MSMS, GC-MS).
He started working in the field of TDM since 1982 with his PhD thesis on cyclosporine, and is author or co-author of more than 180 peer-reviewed manuscripts and nine textbook chapters. He has presented at more than 200 conferences on invitation. Most of his work was dedicated to immunosuppressive drugs, but he also published works in other clinical chemistry or TDM/TOX areas. Pierre Wallemacq is the past-president of the Royal Belgian Society of Clinical Chemistry (SRBCC-KBVKC), and is the current president of the Belgian and Luxemburg society of Toxicology (BLT). He is member of the Editorial Boards of several International Journals such as Therapeutic Drug Monitoring (TDM), Clinical Biochemistry (CLB), Clinical Chemistry and Laboratory Medicine (CCLM). Since July 2009, he serves as Associate Editor for Clinical Biochemistry. He received the IATDMCT C.E. Pippenger award in 2011 for outstanding contribution to Therapeutic drug Monitoring, and was nominated member of the Royal Belgian Academy of Medicine (ARMB) in 2012.
IATDMCT, 4 Cataraqui Street Suite 310
Kingston, ON, K7K 1Z7, Canada
